A carregar...

A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer

Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Oncol
Main Authors: Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., Poirier, B.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6380645/
https://ncbi.nlm.nih.gov/pubmed/30853812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!